Sign In
Buy ALPMY
$13.40
-0.200 (-1.47%)
At Close: Jun 03, 2026
Astellas Targets ¥4.3 Trillion Profit Push As Xtandi Pressure Builds
01:18pm, Tuesday, 26'th May 2026
Astellas Pharma (ALPMY) is trying to give investors a new growth story as Xtandi, its blockbuster prostate cancer drug co-marketed with Pfizer (PFE), moves clos
MRK Stock Gains After CHMP Backs Keytruda Combo for Bladder Cancer
01:26pm, Monday, 25'th May 2026
Merck jumps after CHMP backs Keytruda plus Padcev for certain bladder cancer patients, a combo with the potential to expand treatment options.
Are Medical Stocks Lagging Astellas Pharma (ALPMY) This Year?
10:40am, Wednesday, 13'th May 2026
Here is how Astellas Pharma Inc. (ALPMY) and BillionToOne (BLLN) have performed compared to their sector so far this year.
Astellas Pharma Inc. (ALPMY) Q4 2026 Earnings Call Transcript
12:31am, Tuesday, 28'th Apr 2026
Astellas Pharma Inc. (ALPMY) Q4 2026 Earnings Call Transcript
Are Medical Stocks Lagging Arcellx (ACLX) This Year?
10:45am, Monday, 27'th Apr 2026
Here is how Arcellx, Inc. (ACLX) and Astellas Pharma Inc. (ALPMY) have performed compared to their sector so far this year.
Is Astellas Pharma (ALPMY) Stock Outpacing Its Medical Peers This Year?
10:41am, Friday, 10'th Apr 2026
Here is how Astellas Pharma Inc. (ALPMY) and Adlai Nortye Ltd. Sponsored ADR (ANL) have performed compared to their sector so far this year.
Astellas Pharma Inc. (ALPMY) Discusses R&D Strategy and Focus Areas in Innovative Healthcare Transcript
06:22pm, Monday, 06'th Apr 2026
Astellas Pharma Inc. (ALPMY) Discusses R&D Strategy and Focus Areas in Innovative Healthcare Transcript
Is Astellas Pharma (ALPMY) Outperforming Other Medical Stocks This Year?
10:42am, Wednesday, 25'th Mar 2026
Here is how Astellas Pharma Inc. (ALPMY) and Cardinal Health (CAH) have performed compared to their sector so far this year.
Vir Biotechnology: Up On Prostate Data And Astellas Deal - I'm (Long-Term) Bullish
01:30pm, Tuesday, 24'th Feb 2026
Vir Biotechnology, Inc. surges on positive Phase 1 data for VIR-5500 and a major global partnership with Astellas in prostate cancer. VIR-5500 demonstrated a favorable safety profile and 45% ORR at hi
Astellas collaborates with Vir to develop its experimental prostate cancer drug
05:08pm, Monday, 23'rd Feb 2026
Japan's Astellas and Vir Biotechnology said on Monday they will together develop and commercialize the U.S. drug developer's prostate cancer experimental drug.
- Astellas and Vir Biotechnology to co-develop and co-commercialize VIR-5500 through a sharing of expenses and revenues - - Astellas to lead commercialization of VIR-5500 in the U.S. with Vir Biotechn
India's Lupin clears patent hurdle with Astellas Pharma, keeps Mirabegron sales in US
10:14pm, Monday, 09'th Feb 2026
Indian drugmaker Lupin said on Tuesday it has settled a patent infringement dispute with Japan's Astellas Pharma over the bladder disorder drug Mirabegron, allowing it to continue selling the product
Astellas Pharma (OTCMKTS:ALPMY) Shares Pass Above Fifty Day Moving Average – What’s Next?
04:36am, Wednesday, 04'th Feb 2026
Astellas Pharma Inc. (OTCMKTS:ALPMY - Get Free Report) shares passed above its 50-day moving average during trading on Tuesday. The stock has a 50-day moving average of $13.56 and traded as high as $1
Astellas Pharma Inc. (ALPMY) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
09:16pm, Monday, 12'th Jan 2026
Astellas Pharma Inc. (ALPMY) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Astellas to Present at 44th Annual J.P. Morgan Healthcare Conference
06:30pm, Tuesday, 06'th Jan 2026
TOKYO, Jan. 6, 2026 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced it will present at the 44th Annual J.P. Morgan Healthcare Conference
